Ariel Lu is a China Associate in the Corporate practice. Her practice focuses on initial public offerings and regulatory compliance of Hong Kong listed companies.
Ms. Lu is fluent in English, Mandarin, and Cantonese.
East China University of Political Science and Law, LL.B.
The University of Hong Kong, J.D.
Advised Morgan Stanley, CICC Securities and Credit Suisse as the joint sponsors in the US$281 million global offering and listing of SciClone Pharmaceuticals on the Main Board of the Hong Kong Stock Exchange.
Advised Weihai City Commercial Bank, the only city commercial bank with outlets that cover all prefecture-level cities in Shandong Province in China, on its US$365 million Hong Kong IPO and H-share listing in Hong Kong.
Advised Morgan Stanley and CLSA as the joint sponsors in the HK$2.8 billion global offering and listing of Jinxin Fertility Group, a leading assisted reproductive services provider in China and the United States, on the Main Board of the Hong Kong Stock Exchange.
Advised CCB International as the sole sponsor in the HK$1.37 billion global offering and listing of Dexin China Holdings, a leading comprehensive property developer based in Zhejiang Province, China, on the Main Board of the Hong Kong Stock Exchange.
Advised DaFa Properties, a property development company headquartered in Shanghai, in its HK$740 million global offering and listing on the Main Board of the Hong Kong Stock Exchange.
Advised listed companies, including the Bank of Tianjin and CIMC in relation to its regulatory compliance under the Hong Kong Listing Rules and other relevant law and regulations.